Page 2 - ENT 2026 e-program book final
P. 2

7876_Acarizax Ads_A4 Poster_1.ai      210x297mmH

                                                                                                                                     TABLE OF CONTENTS








           With more Allergy Immunotherapy options, you can treat more patients....
                      IT’S YOUR MOVE.                                                                                                                              02           WELCOME MESSAGE











                                                                                                                                                                   06           ORGANIZING COMMITTEE





                                                                                                                                                                   08           PROGRAM






                                                                                                                                                                   13           HONORABLE FACULTY





                                                                                                                                                                   16           INVITED FACULTY






                                                                                                                                                                   24           LOCAL FACULTY






                EFFECTIVE TREATMENT FOR MONO- AND POLYSENSITIZED PATIENTS                                1                                                         53           EXHIBITION FLOOR PLAN




                      ®
          Acarizax is the ONLY APPROVED sublingual tablet for the treatment of
       House Dust Mite induced Allergic Rhinitis and Allergic Asthma in Hong Kong                              2,3*                                                54           ACKNOWLEDGEMENT



                   Once-daily tablet for convenient dosing to suit a busy lifestyle                  3




      * Indication: Diagnoised by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) - adolescent and adult patients (12-65 years) with persistent moderate to severe house dust
      mite allergic rhinitis despite use of symptom-relieving medication; Adult patients (18-65 years) with house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. 3
      References: 1. Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J. E™ective treatment of housse dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-con-
      trolled phase III trial. J Allergy Clin Immunol. 2016;137(2):444-451. 2. Drug Search Data Base, Hong Kong Department of Health website: https://www.drugo¢ce.gov.hk/eps/drug/productSearch OneFieldAction2 as accessed on 7 Sep 2022. 3. Abbott ®
      ACARIZAX 12 SQ-HDM oral lyophilizate HKPI, December 2022.
      Abbreviated Prescribing Information: Product name: ACARIZAX 12 SQ-HDM oral lyophilisate. Active ingredient: Standardised allergen extract from Dermatophagoides pteronyssinus and D. farinae. Indications: Diagnosed by clinical history and a
      positive test of house dust mite sensitisation (skin prick test and/or specific IgE) –adolescent and adult patients (12-65 years) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication; Adult patients
      (18-65 years) with house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite  allergic rhinitis. Posology and method of administration: one oral lyophilisate (12 SQ-HDM) daily for 3
      years with reference to International treatment guidelines. Sublingual route. The first oral lyophilizate should be taken under medical supervision, and patient should be monitored for at least half an hour. Contraindications: Hypersensitivity to Gelatine
      (fish source), mannitol, sodium hydroxide; Patients with FEV1 < 70% of predicted value (after adequate pharmacological treatment) at initiation of treatment; severe asthma exacerbation within the last 3 months; patients with asthma and concomitant
      acute respiratory tract infection; active or poorly controlled autoimmune diseases, immune defects, immunodeficiencies, immunosuppression or malignant neoplastic diseases with current disease relevance; acute severe oral inflammation or oral
      wounds. Special warnings and precautions for use: Asthma exacerbation; Reduction in other asthma control medication; Severe systemic allergic reactions – recommendation for medical supervision at first oral lyophilisate intake; Oral inflammation; Local
      allergic reactions; Eosinophilic esophagitis; Autoimmune diseases in remission; Food allergy (trace of fish protein present). Interactions: Concomitant therapy with symptomatic anti-allergic drugs may increase the tolerance level of the patient to
      immunotherapy. Fertility, pregnancy and lactation: Acarizax treatment should not be initiated during pregnancy. If pregnancy occurs during treatment, the treatment may be continued after medical evaluations. Effects on ability to drive and use
      machines: no or negligible influence. Undesirable effects: Very common: nasopharyngitis, ear pruritus, throat irritation, lip oedema, oedema mouth, oral pruritus; Common: bronchitis, pharyngitis, rhinitis, sinusitis, dysgeusia, asthma, dysphonia, dyspnoea,
      oropharyngeal pain, pharyngeal oedema, abdominal pain, diarrhea, nausea, oral discomfort, oral mucosal erythema, paraesthesia oral, stomatitis, tongue oedema, vomiting.
      Date of revision: Jun 2020
      ABBOTT LABORATORIES LTD.                              2                                                                                                                      1
      20/F., AIA Tower, 183 Electric Road, North Point, Hong Kong.                                       HKG2286198
      Tel: 2566 8711 Fax: 2219 7712
   1   2   3   4   5   6   7